Tune Therapeutics Secures $175M to Advance Epigenetic Silencing Platform into Clinical Trials

Durham, NC and Seattle, WA, January 12, 2025 (Business Wire) -- Tune Therapeutics has raised $175 million in Series B funding to advance its TEMPO-based epigenetic silencing drug, Tune-401, for chronic hepatitis B. Unlike traditional gene-editing technologies, TEMPO adjusts gene expression without permanently altering DNA, offering a novel therapeutic approach. This funding will support clinical trials in New Zealand and Hong Kong, highlighting Tune’s potential to reshape genetic medicine.

Read full article here.